0
Signin
countryflagUS

18889881171

AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%

Equillium Inc

Healthcare US EQ

1.65USD
0.04(2.48%)

Last update at 2024-04-22T20:00:00Z

Day Range

1.581.71
LowHigh

52 Week Range

0.451.35
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.42800M -39.05200M -29.81300M -25.60000M -13.25000M
Minority interest - - - - -
Net income -107.70700M -38.98000M -29.76800M -25.57700M -13.25000M
Selling general administrative 17.24M 11.41M 10.16M 9.09M 3.67M
Selling and marketing expenses - - - - -
Gross profit 15.76M - - - 0.00000M
Reconciled depreciation 0.12M 0.07M 0.04M 0.02M 0.00610M
Ebit -62.07600M -37.85800M -29.59300M -26.75000M -8.62110M
Ebitda -15.97800M -37.78600M -29.54800M -26.72700M -8.61500M
Depreciation and amortization 46.10M 0.07M 0.04M 0.02M 0.00610M
Non operating income net other - -0.25200M 0.79M 1.45M -2.07210M
Operating income -62.07600M -37.78600M -29.54800M -26.72700M -8.61500M
Other operating expenses 54.79M 37.79M 29.55M 26.73M 8.62M
Interest expense 1.05M 1.07M 1.10M 0.28M 2.56M
Tax provision - - - - -
Interest income 0.42M 0.06M 0.48M 1.39M 0.34M
Net interest income -0.63300M -1.01600M -0.62300M 1.11M -2.21789M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 45.28M -0.07200M -0.04500M -0.02300M 0.14M
Total revenue 15.76M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 54.79M 37.79M 29.55M 26.73M 8.62M
Cost of revenue - - - - 0.00000M
Total other income expense net -0.35200M -1.26600M -0.26500M 1.13M -4.63500M
Discontinued operations - - - - -
Net income from continuing ops -62.42800M -39.11100M -29.81300M -25.60000M -13.25047M
Net income applicable to common shares -62.42800M -39.05200M -29.81300M -25.60000M -13.25000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 78.42M 85.41M 85.43M 55.54M 67.16M
Intangible assets - - - 0.04M 0.02M
Earning assets - - - - -
Other current assets 3.37M 3.05M 3.27M 2.40M 1.25M
Total liab 46.48M 18.90M 15.57M 13.69M 2.23M
Total stockholder equity 31.94M 66.50M 69.85M 41.85M 64.94M
Deferred long term liab - - - - -
Other current liab -6.12200M 5.89M 2.81M 2.01M 0.91M
Common stock 0.00300M 0.00200M 0.00200M 0.00100M 0.00079M
Capital stock 0.00300M 0.00200M 0.00200M 0.00100M 0.00079M
Retained earnings -172.40500M -109.97700M -70.92500M -41.11200M -15.51235M
Other liab 10.38M - 0.05M 0.13M 0.20M
Good will - - - - -
Other assets 3.37M 0.15M -0.25400M -0.10800M -0.06352M
Cash 59.11M 50.37M 23.98M 13.22M 28.51M
Cash and equivalents - - - - -
Total current liabilities 32.04M 8.91M 7.25M 3.88M 2.03M
Current deferred revenue 14.70M - - - -
Net debt -48.92200M -40.38100M -15.70700M -3.53800M -28.30853M
Short term debt 6.12M 1.80M 1.67M - -
Short long term debt 5.71M 1.43M 1.67M - -
Short long term debt total 10.19M 9.98M 8.28M 9.68M 0.20M
Other stockholder equity 204.27M 176.62M 141.07M 82.94M 80.44M
Property plant equipment 1.58M 0.24M 0.24M 0.09M 0.06M
Total current assets 77.23M 83.76M 85.43M 55.54M 67.16M
Long term investments - - - - -
Net tangible assets 31.94M 66.50M 69.85M 41.85M 64.94M
Short term investments 11.92M 30.34M 58.18M 39.92M 37.40M
Net receivables 2.84M - - - -
Long term debt 3.24M 8.75M 8.28M 9.68M 0.20M
Inventory - - - - -
Accounts payable 17.34M 1.23M 2.77M 1.87M 1.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.08M -0.13800M -0.29700M 0.02M 0.00528M
Additional paid in capital - - - - -
Common stock total equity - 0.00200M 0.00200M 0.00100M 0.00079M
Preferred stock total equity - - - - -
Retained earnings total equity - -109.97700M -70.92500M -41.11200M -15.51235M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 0.15M -0.23900M -0.09300M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 1.19M 1.65M 0.25M 0.11M 0.06M
Capital lease obligations 1.23M 1.24M - - -
Long term debt total - 8.75M 8.28M 9.68M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 18.68M 27.46M -18.59200M -2.09200M -37.39947M
Change to liabilities 27.59M 1.52M 0.89M 1.83M 1.44M
Total cashflows from investing activities 18.68M 27.41M -18.59200M -2.16600M -37.43433M
Net borrowings -1.42900M -1.42900M -1.42900M 9.88M 1.60M
Total cash from financing activities -1.21500M 31.06M 53.95M 9.84M 66.37M
Change to operating activities 0.35M 3.28M 0.36M -0.06400M -0.54200M
Net income -62.42800M -39.05200M -29.81300M -25.60000M -13.25047M
Change in cash 8.74M 26.38M 10.76M -15.28900M 21.40M
Begin period cash flow 50.37M 23.98M 13.22M 28.51M 7.10M
End period cash flow 59.11M 50.37M 23.98M 13.22M 28.51M
Total cash from operating activities -8.73300M -32.08100M -24.62400M -22.94900M -7.52625M
Issuance of capital stock 0.00000M 29.91M 53.78M 0.00000M 64.48M
Depreciation 0.12M 0.07M 0.04M 0.02M 0.00610M
Other cashflows from investing activities - - - -2.09200M -37.39947M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -2.83800M -2.83800M -2.83800M -2.83800M -
Sale purchase of stock - 1.15M 53.95M -0.15600M 64.48M
Other cashflows from financing activities 22.76M 1.15M 0.16M 10.15M 1.89M
Change to netincome 28.28M 4.65M 3.63M 2.23M 3.00M
Capital expenditures 0.28M 0.06M 0.20M 0.07M 0.03M
Change receivables - - - - -
Cash flows other operating - 0.18M -0.41000M -1.11500M 1.28M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 26.39M 10.73M -15.27900M 21.40M
Change in working capital 0.02M 1.70M 1.25M 0.71M 0.30M
Stock based compensation 4.84M 4.41M 3.82M 2.25M 0.44M
Other non cash items 48.72M 0.24M 0.34M 0.05M 4.98M
Free cash flow -9.01200M -32.13800M -24.82600M -23.02300M -7.56111M

Fundamentals

  • Previous Close 1.61
  • Market Cap24.05M
  • Volume55696
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.15500M
  • Revenue TTM42.63M
  • Revenue Per Share TTM1.24
  • Gross Profit TTM 15.76M
  • Diluted EPS TTM-0.22

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EQ
Equillium Inc		 0.04 2.48% 1.65 - 1.25 0.56 1.00 3.15
NVO
Novo Nordisk A/S		 2.55 2.08% 125.26 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.76 3.07% 126.26 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.64 1.43% 399.92 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 2.35 2.71% 89.17 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium Inc

2223 Avenida De La Playa, La Jolla, CA, United States, 92037

Key Executives

Name Title Year Born
Mr. Daniel Mark Bradbury Exec. Chairman 1961
Mr. Bruce D. Steel C.F.A. Co-Founder, CEO & Director 1966
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 1982
Mr. Jason A. Keyes Chief Financial Officer 1971
Ms. Christine Zedelmayer M.B.A., P.M.P. Sr. VP & COO 1970
Mr. Michael Moore VP of Investor Relations & Corp. Communications NA
Matthew Ritter Ph.D. Sr. VP of Corp. Devel. NA
Dr. Krishna R. Polu M.D. Consultant 1973
Mr. Joel M. Rothman Chief Devel. Officer 1969

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).